Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of NVDX3
NCT06532253Phase 2Recruiting
- Sponsor
- Novadip Biosciences
- Start
- Aug 2024
- Primary completion
- Mar 2036
- Modality
- Implantable Devices, Implantable Hydrogels, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of NVD-X3 in distal radius fracture, degenerative lumbar spondylolisthesis (DLS), sponsored by Novadip Biosciences. Started Aug 2024; status: recruiting.
02
Drugs
NVD-X3
03
Conditions
distal radius fracturedegenerative lumbar spondylolisthesis (DLS)
Beyond the preview
Go deeper on NCT06532253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06532253.